Table 2 Overall response rates in the response-evaluable population

From: Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study

 

East Asian patientsa

Japanese patients

Response, n (%)

DRd (n = 51)

Rd (n = 43)

DRd (n = 20)

Rd (n = 15)

ORRb

46 (90.2)

31 (72.1)

18 (90.0)

9 (60.0)

sCR

17 (33.3)

5 (11.6)

9 (45.0)

1 (6.7)

CR

10 (19.6)

4 (9.3)

1 (5.0)

0 (0.0)

VGPR

11 (21.6)

8 (18.6)

5 (25.0)

4 (26.7)

PR

8 (15.7)

14 (32.6)

3 (15.0)

4 (26.7)

MR

2 (3.9)

3 (7.0)

1 (5.0)

3 (20.0)

SD

3 (5.9)

8 (18.6)

1 (5.0)

3 (20.0)

PD

0 (0.0)

1 (2.3)

0 (0.0)

0 (0.0)

≥CRc

27 (52.9)

9 (20.9)

10 (50.0)

1 (6.7)

≥VGPRd

38 (74.5)

17 (39.5)

15 (75.0)

5 (33.3)

  1. DRd daratumumab/lenalidomide/dexamethasone, Rd lenalidomide/dexamethasone, ORR overall response rate, sCR stringent complete response, CR complete response, VGPR very good partial response, PR partial response, MR minimal response, SD stable disease, PD progressive disease
  2. aPatients from Japan, Korea, and Taiwan
  3. bsCR + CR + VGPR + PR
  4. csCR + CR
  5. dsCR + CR + VGPR
Back to article page